Replies to post #12258 on The Rising Influence of Rising Affluence

[DewDiligence]

…China has won price cuts of more than 50 percent in national-level bargaining with drug companies on about five kinds of costly imported drugs…

That’s why I like ABT’s business model. In emerging markets, ABT doesn’t sell expensive patented drugs, but rather high-quality branded generics that many consumers prefer to locally made drugs.